Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7270MR)

This product GTTS-WQ7270MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7270MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ463MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ10643MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ3781MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ15099MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ15270MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ1152MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ13928MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ773MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AB0024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.